We assessed the impact of the publication of trials and changes in recommendations on the rates of prostate-specific antigen ( 
In early 2009, the publication of two large clinical trials reported substantial rates of overdiagnosis of prostate cancer with routine prostate-specific antigen (PSA) screening (1, 2) . These results led many organizations to change their recommendations on PSA screening (3) (4) (5) . Both the trial publications and the new recommendations stimulated by them received substantial media coverage.
We studied PSA testing in men aged 40 to 64 years enrolled in a large private insurance plan using administrative data from Clinformatics Data Mart, which covered more than 1.5 million men aged 40 to 64 in each year (6) . The study was institutional review board exempt because the data contained no personal identifiers. We excluded those with any diagnosis of prostate cancer or prostate mass in the prior 2 years (International Classification of (7, 8) . We chose a linear model because the plot of the observed rates over time appeared linear, and residual analysis suggested the model fitted well. We also calculated yearly PSA testing rates by age category. For those analyses, we included only men with coverage for the entire year. We repeated the joinpoint analyses and calculation of yearly rates separately for each census region: Northwest, Midwest, South, and West (9) . A logistic regression was used to evaluate the interactions of age, region, and time on receipt of PSA testing based on individual-level data. The data do not indicate race or ethnicity. A P value of less than.05 was considered statistically significant. Table 1 presents the rates of PSA testing in 2001 and 2011, stratified by age and region. Because of the large numbers of subjects, all differences between 2001 and 2011 were statistically significant, although many changes were quite small. For men aged 40 to 49 years, PSA testing rates increased slightly in all regions (3.6% increase, from 12.1% to 15.7%; 95% confidence interval [CI] = 3.5% to 3.7%), with a steeper increase in the South (5.6% increase, from 14.3% to 19.9%; 95% CI = 5.4% to 5.8%). From 2001 to 2011, the overall PSA testing rates increased slightly for men aged 50 to 59 years (1.5% increase, from 32.7% to 34.2%; 95% CI = 1.3% to 1.7%) and decreased slightly for men aged 60 to 64 years (0.7% decrease, from 42.7% to 42.0%; 95% CI = 0.3% to 1.0%). In men aged 50 to 59 years and 60 to 64 years, PSA testing rates declined slightly from 2001 to 2011 in most regions, although rates in the South increased over that period (4.1% increase, 95% CI = 3.8% to 4.3% for men aged 50 to 59 years; 1.9% increase, 95% CI = 1.3% to 2.4% for men aged 50 to 59 and 60 to 64, respectively). We repeated the plots shown in Figure 1 separately for each region (not shown). The decline in the slope of rate of testing in men aged 40 to 49 years seen in mid-2009 in Figure 1 was restricted to men in the West region. Similar to Figure 1 , the slopes of the rate of PSA testing in men aged 50 to 59 years and 60 to 64 years did not change for any region over the period from 2009 to 2011.
It might be argued that not enough time had elapsed to measure the impact of publication of the trials or changes in recommendations on PSA testing. However, we previously found that substantial changes in community practice can occur within days of media coverage of findings (10, 11) .
Cancer screening may differ from other medical interventions in the high level of belief in its effectiveness, both in the American public (12) and among physicians (13, 14) . Approximately 93% of primary care physicians surveyed in 2011 had heard of the changes in recommendations (15) . Three-quarters responded that their patients expected them to continue testing, and this expectation may be the biggest barrier to rapid implementation of the new recommendations (15) . The rate of PSA testing showed a deflection point in mid-2009 for men aged 40 to 49 years. This change may be related to the March 2009 publication of the clinical trials. Ironically, neither trial contained men in their 40s, and no organization had recommended routine PSA testing in that age group. Some organizations, such as the American Cancer Society, had recommended PSA testing in African American men before age 50 years, given the more aggressive nature of the disease. Unfortunately, our data contain no information on race or ethnicity.
The limitations of our study include its restriction to men with commercial insurance. Also, we could not exclude men whose PSA test was performed to evaluate a sign or symptom.
In conclusion, neither the publication of the two large trials nor the subsequent changes in recommendations had an obvious effect on PSA screening rates for men aged 50 to 64 years, despite extensive media coverage of these events. The rates for men aged 40 to 49 years went from a steady increase to flat coincident with the trial publications. There seems to be considerable resistance to changing PSA screening practices. Continued public information and assistance to primary care physicians in addressing the question of unnecessary or harmful testing with their patients may be helpful. 
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